Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F24%3A43921389" target="_blank" >RIV/00023752:_____/24:43921389 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43927742

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0091305724001977" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0091305724001977</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pbb.2024.173903" target="_blank" >10.1016/j.pbb.2024.173903</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats

Popis výsledku v původním jazyce

Rationale: Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.Objectives: In this study, we aimed to investigate how selective antagonists of 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors affect the behavioral changes induced by subcutaneous administration of mescaline (at doses of 10, 20, and 100 mg/kg) in rats.Methods: We used adult male Wistar rats in all our experiments. We evaluated locomotor activity using the open field test, and assessed sensorimotor gating deficits by measuring prepulse inhibition (PPI) of acoustic startle reaction (ASR).Results: While the highest dose of mescaline induced hyperlocomotion (p &lt; 0.001), which almost all the other antagonists reversed (p &lt; 0.05–0.001), the PPI deficits were selectively normalized by the 5-HT2A antagonist (p &lt; 0.05–0.01). The 5-HT2C antagonist partially reversed the small PPI deficit induced by lower doses of mescaline (p = 0.0017).Conclusion: Our findings suggest that mescaline-induced changes in behavior are primarily mediated by the 5-HT2A receptor subtype, with less pronounced contributions from the 5-HT2C receptor. The other antagonists had limited effects.

Název v anglickém jazyce

Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats

Popis výsledku anglicky

Rationale: Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.Objectives: In this study, we aimed to investigate how selective antagonists of 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors affect the behavioral changes induced by subcutaneous administration of mescaline (at doses of 10, 20, and 100 mg/kg) in rats.Methods: We used adult male Wistar rats in all our experiments. We evaluated locomotor activity using the open field test, and assessed sensorimotor gating deficits by measuring prepulse inhibition (PPI) of acoustic startle reaction (ASR).Results: While the highest dose of mescaline induced hyperlocomotion (p &lt; 0.001), which almost all the other antagonists reversed (p &lt; 0.05–0.001), the PPI deficits were selectively normalized by the 5-HT2A antagonist (p &lt; 0.05–0.01). The 5-HT2C antagonist partially reversed the small PPI deficit induced by lower doses of mescaline (p = 0.0017).Conclusion: Our findings suggest that mescaline-induced changes in behavior are primarily mediated by the 5-HT2A receptor subtype, with less pronounced contributions from the 5-HT2C receptor. The other antagonists had limited effects.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacology Biochemistry and Behavior

ISSN

0091-3057

e-ISSN

1873-5177

Svazek periodika

245

Číslo periodika v rámci svazku

"Article number: 173903"

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1-8

Kód UT WoS článku

001409048600001

EID výsledku v databázi Scopus

2-s2.0-85209389426